Drug Profile
Research programme: PARP-1 inhibitors - IMPACT Therapeutics
Latest Information Update: 08 Jun 2023
Price :
$50
*
At a glance
- Originator IMPACT Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer